Off-Label Prescriptions in Italian Hospices: A National Survey

被引:14
|
作者
Toscani, Franco [1 ]
Di Giulio, Paola [2 ]
Campi, Rita [3 ]
Pellerin, Ivanoe [4 ]
De Luca, Anna [5 ]
Casale, Giuseppe [6 ]
机构
[1] Lino Maestroni Fdn Palliat Med Res Inst, I-26100 Cremona, Italy
[2] Univ Turin, Dept Microbiol & Publ Hlth, Turin, Italy
[3] Mario Negri Inst Pharmacol Res, Lab Mother & Child Hlth, Milan, Italy
[4] Hosp Legnano, Palliat Care Unit, Legnano, Italy
[5] Osped San Giovanni Battista Torino, Palliat Care Unit, Turin, Italy
[6] Antea Fdn, Rome, Italy
关键词
Off-label; hospice; palliative medicine; SC drugs; prescriptions in hospices; symptomatic prescriptions; CONTINUOUS SUBCUTANEOUS INFUSION; PALLIATIVE CARE; UNITED-KINGDOM; CANCER PAIN; DRUGS; MANAGEMENT; MEDICINE; MEDICATION; PHYSICIANS; KETOROLAC;
D O I
10.1016/j.jpainsymman.2008.11.014
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Off-label prescription is part, of routine care in palliative medicine, but no information is available about the situation in Italy. A cross-sectional observational survey was undertaken on all 66 Italian palliative care freestanding inpatient units to describe off-label prescriptions. Data were collected on 507 patients. Each prescribed drug was matched with Italian Marketing Authorization indications: 159 drugs off-label (4.5% of all prescribed drugs) for the stated indication, were given to 128 patients (25.2%), and drugs unlicensed for subcutaneous injection were given, to 14 7 patients (85.4% of all subcutaneous prescriptions, excluding insulin and heparin). The off-label prescriptions were subsequently evaluated by referring to the Italian National Pharmaceutical Formulary (INPF) and the British Palliative Care Formulary (PCF2). Although drugs are frequently Prescribed off-label in inpatient palliative care units in Italy, this strategy was not always backed by clinical evidence, and in some cases, official/authoritative sources, such as INPF and PCF2 did not support. it. Clinical trials and/or agreed international guidelines are needed to support the off-label,use of the most widely prescribed drugs in palliation. J Pain Symptom Manage 2009;38:365-371. (C) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 50 条
  • [31] Off-label use and manipulations of antiepileptic drugs in children: Analysis of the outpatient prescriptions in a tertiary center
    Kuchenbuch, Mathieu
    Chemaly, Nicole
    Henniene, Kassem M. B.
    Kaminska, Anna
    Chiron, Catherine
    Nabbout, Rima
    EPILEPSY & BEHAVIOR, 2018, 82 : 133 - 139
  • [32] Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care - a nationwide study
    Olsson, J.
    Kimland, E.
    Pettersson, S.
    Odlind, V.
    ACTA PAEDIATRICA, 2011, 100 (09) : 1272 - 1275
  • [33] The use of unlicensed and off-label medicines in the neonate
    Conroy, S
    McIntyre, J
    SEMINARS IN FETAL & NEONATAL MEDICINE, 2005, 10 (02): : 115 - 122
  • [34] Off-Label Uses of Omalizumab
    David El-Qutob
    Clinical Reviews in Allergy & Immunology, 2016, 50 : 84 - 96
  • [35] Off-Label Uses of Omalizumab
    El-Qutob, David
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2016, 50 (01) : 84 - 96
  • [36] "Off-Label" Use of DNS
    Wala, Fatema Bannat
    Cotton, Chase
    DIGITAL THREATS: RESEARCH AND PRACTICE, 2022, 3 (03):
  • [37] Solutions for off-label therapy
    Schmidt, WA
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2003, 62 : 54 - 56
  • [38] Off-Label Medications in Pediatrics
    Unni, Jeeson C.
    Joseph, Ranjit Baby
    INDIAN JOURNAL OF PEDIATRICS, 2019, 86 (12): : 1149 - 1149
  • [39] In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry
    Esposito, Silvano
    Pagliano, Pasquale
    De Simone, Giuseppe
    Guarino, Amedeo
    Pan, Angelo
    Brambilla, Paola
    Mastroianni, Claudio
    Lichtner, Miriam
    Brugnaro, Pierluigi
    Carretta, Anna
    Santantonio, Teresa
    Brindicci, Gaetano
    Carrega, Giuliana
    Montagnani, Francesca
    Lapadula, Giuseppe
    Spolti, Anna
    Luzzati, Roberto
    Schiaroli, Elisabetta
    Scaglione, Vittoria
    Pallotto, Carlo
    Tacconi, Danilo
    Quintieri, Francesco
    Trecarichi, Enrico
    INFECTION, 2024, 52 (03) : 1087 - 1097
  • [40] How to handle off-label prescriptions of rupatadine, a second-generation antihistamine and PAF antagonist: a review
    Izquierdo, Inaki
    Casas, Laia
    Cabrera, Susana
    Fernandez, Alberto
    DRUGS IN CONTEXT, 2024, 13